SIERRA ONCOLOGY

SRRA NASDAQ
0.5550
-0.0183
-3.19%
After Hours: 0.5550 0 0.00% 16:08 07/17 EDT
Open
0.5819
Prev Close
0.5733
High
0.6049
Low
0.5462
Volume
857.88K
Avg Vol (3M)
1.12M
52 Week High
3.030
52 Week Low
0.5330
% Turnover
1.64%
Market Cap
29.11M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers SIERRA ONCOLOGY SRRA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
MORE >

Recently

Name
Price
%Change